Content
and Copyright
i
Superseded
This Document Has Been Replaced By:
i
Retired
This Document Has Been Retired
i
Up-to-date Information
This is the latest update:
Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition
-
Published Date:
April 17 2020
-
Source:Acta Neuropathol. 139(6):1071-1088
-
Language:English
-
Public Access Version Available on:
June 01, 2021, 12:00 AM
Details:
-
Alternative Title:Acta Neuropathol
-
Personal Author:
-
Description:Brain tumors are the most common solid tumors of childhood, and the genetic drivers and optimal therapeutic strategies for many of the different subtypes remain unknown. Here, we identify that bithalamic gliomas harbor frequent mutations in the EGFR oncogene, only rare histone H3 mutation (in contrast to their unilateral counterparts), and a distinct genome-wide DNA methylation profile compared to all other glioma subtypes studied to date. These EGFR mutations are either small in-frame insertions within exon 20 (intracellular tyrosine kinase domain) or missense mutations within exon 7 (extracellular ligand-binding domain) that occur in the absence of accompanying gene amplification. We find these EGFR mutations are oncogenic in primary astrocyte models and confer sensitivity to specific tyrosine kinase inhibitors dependent on location within the kinase domain or extracellular domain. We initiated treatment with targeted kinase inhibitors in four children whose tumors harbor EGFR mutations with encouraging results. This study identifies a promising genomically-tailored therapeutic strategy for bithalamic gliomas, a lethal and genetically distinct brain tumor of childhood.
-
Subject:
-
Pubmed ID:32303840
-
Pubmed Central ID:PMC7792550
-
Document Type:
-
Collection(s):
-
Main Document Checksum:
- File Type:
-
Supporting Files:No Additional Files
No Related Documents.
Email
CDC-INFO
